HIV and hepatitis C co-infection: The role of HAART in HIV/hepatitis C virus management

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 546-552

  Jones, Michelle ^a   Núñez, Marina ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; hepatotoxicity; highly active antiretroviral therapy; HIV hepatitis Cvirus co infection; liver fibrosis progression

Indexed keywords

DIDANOSINE; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR;

CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VIRAL CLEARANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; TREATMENT OUTCOME;

EID: 80054948562     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bcbd9     Document Type: Review

References (75)

1. Adih WK, Selik RM, Hu X. Trends in diseases reported on US death certificates that mentioned HIv infection, 1996-2006. JIAPAC 2011; 10:5-11.
2. Panel on AntiretroviralGuidelines forAdults andAdolescents. Guidelines for the use of antiretroviral agents in HIv-1-infected adults and adolescents. Department of Health and Human Services. 10 January 2011. pp. 1-166. http:// www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 15 June 2011]
3. DHHS/CDC. Guidelines for Prevention and Treatment of Opportunistic Infections in HIv-Infected Adults and Adolescents.MMWR 2009/vol. 58/No. RR-4. http://aidsinfo.nih.gov/contentfiles/Adult-OI-041009.pdf. [Accessed 18 June 2011]
4. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIv infection. 2010 Recommendations of the International AIDS Society: USA panel. J Am Med Assoc 2010; 304:321-333.
5. Clumeck N, Pozniak A. EACS Executive Committee. European AIDS Clinical Society guidelines for the clinical management and treatment of HIv-infected clinical management and treatment of HIv-infected adults. HIv Med 2008; 9:65-71; http://www.europeanaidsclinicalsociety.org/ guidelinespdf/1-Treatment-of-HIv- Infected-Adults.pdf.[Accessed vJune 2011]. (Pubitemid 351228129)
6. EACS recommendations for chronic hepatitis B and C. http://www. europeanaidsclinicalsociety. org/guidelinespdf/3-Chronic-Hepatitis-B-&-C. pdf. [Accessed vJune 2011]
7. British HIv Association guidelines for the treatment of HIv-1-infected adults with antiretroviral therapy 2008. http://www.bhiva.org/Treatmentof HIv1-2008.aspx. [Accessed vJune 2011]
8. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155.
9. Saves M, vandentorren S, Daucourt v, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999; 13:F115-F121.
10. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIv and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283:74-80. (Pubitemid 30038386)
11. Núñez M, Ríos P, Martín-Carbonero L, et al. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:65-68. (Pubitemid 34506688)
12. Maida I, Babudieri S, Selva C, et al. Liver enzyme elevation in hepatitis C virus (HCv)-HIv-coinfected patients prior and after initiation of HAART: role of HCv genotypes. AIDS Res Hum Retroviruses 2006; 22:139-143. (Pubitemid 43277149)
13. Torti C, Lapadula G, Puoti M, et al. Influence of genotype vhepatitis C coinfection on Liver enzymeelevation in HIv-1-positive patients aftercommencement of a new highly active antiretroviral regimen: results from the EPOKAMASTER Cohort. J Acquir Immune Defic Syndr 2006; 41:180-185.
14. Yunihastuti E, Lee S, Gani RA, et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCv immune restoration disease in HIv/HCv co-infected patients commending ART. Clin Immunol 2011; 138:32-39.
15. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIv-infected patients with HIv protease inhibitors: an 'immune restoration disease'? AIDS 1998; 12:2289-2293. (Pubitemid 28526408)
16. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIv-infected patients with highly active antiretroviral therapy. HIv Med 2000; 1:107-115.
17. Ofotokun I, Smithson SE, Lu C, et al. Liver enzyme elevation and immune reconstitution among treatment naïve HIv-infected patients instituting antiretroviral therapy. Am J Med Sci 2007; 334:334-341. (Pubitemid 351339266)
18. Stone SF, Lee S, Keane NM, et al. Association of increased hepatitis C virus (HCv)-specific IgG and soluble CD26 dipeptidyl peptidase Iv enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCv-coinfected patients. J Infect Dis 2002; 186:1498-1502. (Pubitemid 35286121)
19. Didanosine full prescribing information. Princeton, NJ: Bristol-Myers Squibb, March 2007. http://www.videx.com. [Accessed 8 June 2011]
20. Igoudjil A, Abbey-Toby A, Begriche K, et al. High doses of stavudine induce fat wasting and mild Liver damage without impairing mitochondrial respiration in mice. Antivir Ther 2007; 12:389-400. (Pubitemid 46787984)
21. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189. (Pubitemid 34032559)
22. Heil EL, Townsend M. Incidence of severe hepatotoxicity related to antiretroviral therapy in HIv/HCv coinfected patients. AIDS Res Treat 2010; 856542.
23. Wit F, Weverling G, Weel J, et al. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31. (Pubitemid 34666910)
24. Lamar ZS, Nú nez M. Higher risk of severe drug-induced Liver injury among Hispanic HIv-infected patients after initiation of highly active antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic) 2011; 10:183-186.
25. Palmon R, Koo B, Shoultz D, Dieterich D. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:340-345. (Pubitemid 34288886)
26. Martín-Carbonero L, Núñez M, Gonzá lez-Lahoz J, Soriano v. Incidence of Liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIv Clin Trials 2003; 4:115-120. (Pubitemid 36410915)
27. van leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet 2004; 363:1253-1263. (Pubitemid 38496486)
28. Martínez E, Blanco J, Arná iz J, et al. Hepatotoxicity in HIv-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268. (Pubitemid 32592358)
29. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al. A cohort study of nevirapin tolerance in clinical practice: French aquitaine cohort, 1997-1999. Clin Infect Dis 2002; 35:1231-1237. (Pubitemid 35305871)
30. Clotet B, Clumeck N, Katlama C, et al. Safety of etravirine in HIv-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. J Antimicrob Chemother 2010; 65:2450-2454.
31. Sulkowski M. Hepatotoxicity associated with antiretroviral therapy containing HIv-1 protease inhibitors. Semin Liver Dis 2003; 23:183-194.
32. Sulkowski M, Mehta S, Chaisson R, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284. (Pubitemid 39620220)
33. Gathe JC Jr, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIv type-1 infected patients. AIDS Res Hum Retroviruses 2007; 23:216-223. (Pubitemid 46418335)
34. Macias J, Castellano v, Merchante N, et al. Effect of antiretroviral drugs on Liver fibrosis in HIv-infected patients with chronic hepatitis C: impact of nevirapine. AIDS 2004; 18:767-774. (Pubitemid 38535004)
35. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIv and Hepatitis C virus-coinfected patients treated with Interferon plus ribavirin-based therapy: analysis of risk factors. CID 2008; 46:768-774. (Pubitemid 351321564)
36. Moodie EE, Pan-Pai M, Klein MB. Is antiretroviral therapy causing longterm Liver damage? A comparative analysis of HIv-mono-infected and HIv/ Hepatitis C Co-infected cohorts. PLoS ONE 2009; 4:e4517.
37. Fuster D, Planas R, Muga R, et al. Advanced Liver fibrosis in HIv/HCvcoinfected patients on antiretroviral therapy. AIDS Res Human Retro 2004; 20:1293-1297. (Pubitemid 40065924)
38. Mehta S, Thomas DL, Toberson M, et al. The effect of antiretroviral therapy on Liver disease among adults with HIv and hepatitis C coinfection. Hepatology 2005; 41:123-131. (Pubitemid 40066390)
39. Sterling RK, Wilson MS, Sanyal AJ, et al. Impact of highly active antiretroviral therapy on the spectrum of Liver disease in HCv-HIv coinfection. Clin Gastroenterol Hepatol 2004; 2:432-439. (Pubitemid 38561242)
40. Berenguer J, Bellon JM, Miralles P, et al. Association between exposure of Nevirapine and reduced Liver fibrosis progression in patients with HIv and hepatitis C virus coinfection. CID 2008; 46:137-143. (Pubitemid 351263575)
41. Woreta TA, Stucliffe CG, Mehta AH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIv and Hepatitis C virus. Gastroenterology 2011; 140:809-817.
42. McGovern B, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analog use and hepatitis C virus genotype vinfection in HIv seropositive patients. Clin Infect Dis 2006; 43:365-372. (Pubitemid 44078910)
43. Sterling R, Contos MJ, Smith PG, et al. Steatohepatitis: risk factors and disease impact on HIv/HCv coinfection. Hepatology 2008; 47:1118-1127.
44. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIv and hepatitis C virus. AIDS 2005; 19:585-592. (Pubitemid 40543981)
45. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIv-HCv coinfected patients: analysis of risk factors. AIDS 2006; 20:525-531. (Pubitemid 43731596)
46. McGovern BH. Hepatic steatosis in IHv/HCv-coinfected patients: time to reevaluate! Gastroenterology 2011; 140:809-817.
47. Rodriguez-Torres M, Govindarajan S, Sola R, et al. Hepatic steatosis in HIv/ HCv co-infected patients: correlates, efficacy and outcomes of anti-HCv therapy: a paired Liver biopsy study. J Hepatol 2008; 48:756-764.
48. Rector RS, Thyfault JP, Wei Y, Obdah JA. Nonalcoholic fatty Liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14:185-192. (Pubitemid 351314297)
49. Ingiliz P, valantin MA, Duvivier C, et al. Liver damage underlying unexplained aminotransferase elevation in human immunodeficiency virus-1 monoinfected patients in antiretroviral therapy. Hepatology 2009; 49:436-442.
50. Halfon P, Penaranda G, Carrat F, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in HCv monoinfected compared with HIv-HCv co-infected patients. Aliment Pharmacol Ther 2009; 30:61-70.
51. Machado Mv, Oliveria AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/Hepatitis C virus: a metaanalysis of the risk factors. Hepatology 2010; 52:71-78.
52. Brown TT, Mehta SH, Sutcliffe C, et al. Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIv in HIv/Hepatitis C co-infected person. AIDS 2010; 24:811-816.
53. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIv and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
54. Bonacini M, Louie S, Bzowej N,Wohl AR. Survival in patients with HIv infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2045. (Pubitemid 39463357)
55. Ragni Mv, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIv-HCv co-infection. Haemophilia 2009; 15:552-558.
56. Benhamou Y, Di Martino v, Bochet M, et al. Factors affecting Liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287. (Pubitemid 32702341)
57. Mariné-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIv/hepatitis C virus coinfected patients. AIDS 2004; 18:2163-2170. (Pubitemid 39463681)
58. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIv/HCv-coinfected patients with successful HIv suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. (Pubitemid 41772515)
59. verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate Liver fibrosis in HIv-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-270. (Pubitemid 43054201)
60. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeat Liver biopsy in patients coinfected with human immunodeficiency virus/ hepatitis C virus. Hepatology 2009; 50:1056-1063.
61. Reiberger T, Ferlitsch A, Sieghart W, et al. HIv-HCv co-infected patients with low CD4' cell nadirs are at risk for faster fibrosis progression and portal hypertension. J viral Hepat 2010; 17:400-409.
62. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for Liver fibrosis in HIv and hepatitis C virus (HCv) co-infected patients. J viral Hepat 2003; 10:118-125. (Pubitemid 36359849)
63. Mendeni M, Focà E, Gotti D, et al. Evaluation of Liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIv-infected patients without hepatitis C and B infection. Clin Infect Dis 2011; 52:1164-1173.
64. Thorpe J, Saeed S, Moodie EE, Klein MB, Canadian Co-infection Cohort Study (CTN222). Antiretroviral treatment interruption leads to progression of Liver fibrosis in HIv-hepatitis C virus co-infection. AIDS 2011; 25:967-975.
65. Connoy A, Tuner J, Nunez M. Levels of serum markers of Liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIv status and antiretroviral use. AIDS Res Hum Retroviruses 2011; 27.
66. Bani-Sadr F, Bedossa P, Rosenthal E, et al. Does early antiretroviral treatment prevent Liver fibrosis in HIv/HCv-coinfected patients? J Acquir Immune Defic Syndr 2009; 50:234-236.
67. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
68. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIv-infected individuals and the impact of HIv in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
69. Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses in HCv core increase and HCv RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59:1252-1258.
70. Sterling RK, Wegelin JA, Stravitz RT, et al. Similar progression of fibrosis between HIv/HCv-infected and HCv-infected patients: analysis of paired Liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8:1070-1076.
71. Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIv and HCv despite high CD4 cell count. J viral Hepat 2007; 14:806-811. (Pubitemid 47561586)
72. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIv) infection on the progression of Liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035-1040. (Pubitemid 36765298)
73. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to Liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-498. (Pubitemid 36241318)
74. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe Liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133. (Pubitemid 38045883)
75. Reiberger T, Payer BA, Kosi L, et al., for the vienna HIv Coinfection Study Group. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4' cell counts during and after pegylated interferon plus ribavirin therapy in HIv-hepatitis C virus coinfected patients. J Infect Dis 2011; 203:1802-1806.